SBIR/STTR Research Award
A Topical Non-steroidal Anti-inflammatory for Atopic Dermatitis
Award amount
$2,964,464Program and phase
SBIR · Phase IIAward year
2017Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- SIGNUM BIOSCIENCES, INC.
- Proposal award date
- 2017-02-14
- Contract end date
- 2021-01-31
- UEI
- JN5YL5GWN9L7
- Solicitation number
- PA16-302
- Topic code
- NIAID
Research abstract
SUMMARY Atopic dermatitis is a chronic dermatological condition afflicting mostly infants and young childrenCurrent treatments are associated with a wide range of side effects therefore development of novel therapeutic agents that are efficacious and have an improved safety profile is neededAlthough disease etiology has yet to be fully understoodskin inflammation is known to be critically involved in the disease pathologySignum has identified two novel potent topical anti inflammatory agentslead compoundSIGbackup compoundSIGcalled isoprenylcysteinesIPCswith no detectable adverse affectsThe proposed Phase IIB research plan will enable the filing of an investigational new drugINDapplication for the first in human trials in ADIn addition this grant proposal will buttress Post IND clinical efforts by completing additional juvenile safety and continue drug substance and drug product development for Phase II clinical trials NARRATIVE Atopic dermatitis is a chronic pruritic skin disorder afflicting mainly children under the age of fiveCurrent treatmentsalthough efficacious in reducing symptoms are associated with adverse effectsSuccessful pharmaceutical development of topical IPC analog anti inflammatories will provide an important additionaland potentially bettertherapeutic option for people suffering from atopic dermatitis
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- A Topical Non-steroidal Anti-inflammatory for Atopic Dermatitis
- A Topical Non Steroidal Anti-inflammatory for Rosacea
- A Novel Class of Therapeutic Agents for the Treatment of Skin Diseases Associated
- A Novel Class of Topical Pleitropic Anti-Acne Therapeutics
- Phosphoprotein phosphatase 2A, a new target for Alzheimer's Disease interventio
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Manufacturing and Formulation Process Development for a Prophylactic Cholera Phage Cocktail
- A first-in-class product for the clearance of high-risk human papillomaviruses
- A Rapid, Point-of-Care Diagnostic to Identify Viable Sexually Transmitted Infections, Reduce Overtreatment, and Prevent Emerging Antibiotic Resistance
- Optimization, Pharmacokinetics, and Efficacy of an IgG Protease for the Treatment of Immune Thrombocytopenia and Other IgG-Mediated Autoimmune Diseases
- Nebulized ALX1 as a treatment for Pseudomonas aeruginosa infections in bronchiectasis patients
Research funding history
8 SBIR/STTR records share this UEI (2008–2017). Reported award amounts total $10,491,404. Reported amounts are not federal obligations.
Phases: Phase II, Phase I
Agencies: Department of Health and Human Services